TP53 and cancer: (i) Although the selection of predictive biomarkers from genomic targets for clinical cancer therapy is essential for successful treatment, for immunotherapy, the checkpoint blockade of immune cell responses to the treatment agents is more important.413 Unlike the genes that are mutated in cancer cells, such as p53, the immune system is significantly affected by stressors including complex environmental toxicants and endogenous materials.